.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH01_Sitagliptin.Sitagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH01_Sitagliptin.Sitagliptin| name: | Sitagliptin |
| ATC code: | A10BH01 | route: | oral |
| n-compartments | 1 |
Sitagliptin is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor used to improve glycemic control in adults with type 2 diabetes mellitus. It is usually administered orally as a once-daily tablet, often in combination with other antidiabetic drugs. Sitagliptin is approved and widely used today in clinical practice.
Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose of sitagliptin 100 mg tablet.
Herman, GA, et al., & Wagner, JA (2006). Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism 91(11) 4612–4619. DOI:10.1210/jc.2006-1009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16912128
Zhou, C, et al., & Shao, F (2024). Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus. Frontiers in endocrinology 15 1359407–None. DOI:10.3389/fendo.2024.1359407 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38529396
Chen, X, et al., & Hu, P (2016). An open-label, multiple-dose study to assess the pharmacokinetics and tolerability of sitagliptin/metformin fixed-dose combination (FDC) tablet in healthy Chinese adult subjects. International journal of clinical pharmacology and therapeutics 54(9) 705–711. DOI:10.5414/CP202646 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27390052